




DECLARATION OF ALFRED C. NICHOLS, PH.D.

My name is Alfred C. Nichols. I am over 18 years of age and I currently reside in Jacksonville, Alabama. I have personal knowledge of the facts set forth in this declaration.

2. I am presently employed by Jacksonville State University in Jacksonville, Alabama as an Associate Professor of Chemistry.
3. After receiving my Ph.D., I worked at the University of Texas Medical Branch ("UTMB") in Galveston, Texas, where I began studying a specific set of excitatory amino acid neurotransmitter receptors that selectively bind *N*-methyl-D-aspartic acid ("NMDA"). Over-stimulation of these "NMDA receptors" has been implicated in a number of central nervous system disorders. Accordingly, NMDA antagonists are believed to have therapeutic benefit as a result of neuroprotective and anticonvulsant properties.
4. The NMDA receptor sites comprise a subset of excitatory receptors that are activated by L-glutamic acid. The receptor complex also has a strychnine-insensitive binding site for glycine. For channel opening to occur, apparently both glutamate and glycine binding sites must be occupied. Consequently, antagonism of either glutamate or glycine binding inhibits NMDA receptors.
5. My research with NMDA receptors and antagonists led to my work with kynurenic acid derivatives. Kynurenic acid derivatives have been shown to be a competitive inhibitor of glycine binding at the NMDA receptor.
6. My research with kynurenic acid derivatives led to the syntheses of novel 4-hydroxyquinaldic acid derivatives for use as photoaffinity probes for NMDA receptors, which became the subject of U.S. Patent No. 5,028,707 issued in 1991 and U.S. Patent No. 5,344,922 issued in 1994.
7. Continuing research with kynurenic acid derivatives led to the syntheses of novel 4-amino substituted derivatives for use as NMDA antagonists, such as 4-methylamino-5,7-dichloro-2-quinoline carboxylate, which became the subject of U.S. Patent No. 5,493,027 issued in 1996.
8. On or about February 15, 1994, I conceived of a synthesis method of forming a 4-urea derivative of a 4-amino-2-carboxyquinoline compound. I decided that phosgene [COCl_2] may be reactive enough to attach its acyl carbon [C] to the 4-amino group of the 4-amino-2-carboxyquinoline compound, after which, a secondary amine [N] could be attached to the carbonyl group [CO], thereby forming a 4-urea group. I decided that a di-substituted


secondary amine was preferable because (1) it would more likely attach to the carbonyl group [CO] because it was a stronger Lewis base and (2) there was not a risk of it forming a dimer with another quinoline structure. I could not find phosgene [COCl₂] commercially available, but was able to find triphosgene [CO(OCCl₃)₂], which was an acceptable alternative to phosgene. I decided to use diethylamine [NH(ethyl)₂] as the di-substituted amine.

9. On March 23, 1994, I began the first experiment according to the new synthesis method, wherein I first reacted triphosgene with 4-amino-7-chloro-2-carboxyquinoline methyl ester to attach triphosgene's carbonyl group [CO] to the 4-amino group and then reacted diethylamine to attach the secondary amine [N] to the carbonyl group [CO]. I recorded this experiment on page 94A-43 in my Lab Book (Nichols Exhibit 2020), which also documents the expected product having a 4-diethyl urea substitution ((N,N-diethyl)-4-ureido-7-chloro-2-carboxyquinoline methyl ester). However, I was unable to successfully isolate the expected product.
10. On April 11, 1994, I began another synthesis wherein I first reacted triphosgene with 4-amino-5,7-dichloro-2-carboxyquinoline methyl ester to attach triphosgene's carbonyl group [CO] to the 4-amino group and then reacted diethylamine to attach the secondary amine [N] to the carbonyl group [CO]. I recorded this experiment on pages 94A-63 and 94A-64 in my Lab Book (Nichols Exhibit 2030), which also documents the expected product having a 4-diethyl urea substitution ((N,N-diethyl)-4-ureido-5,7-dichloro-2-carboxyquinoline methyl ester) on page 94A-63.
11. I labeled a sample from the April 11, 1994 experiment 94A-64-II. The labels applied to my samples correspond to particular samples from particular pages from my Lab Books. For example, sample 94A-64-II corresponds to sample II from page 64 of my Lab Book No. 94A. I had a NMR spectrum performed on sample 94A-64-II. NMR spectra are used to identify chemical structures. A spectrum data sheet was generated from the NMR spectrum of sample 94A-64-II (Nichols Exhibit 2031), which indicated that the expected product having a 4-diethyl urea substitution ((N,N-diethyl)-4-ureido-5,7-dichloro-2-carboxyquinoline methyl ester) was successfully produced. The NMR spectrum data sheet does not indicate the date that the NMR spectrum was performed; however, page 94A-64 of my Lab Book (Nichols Exhibit 2030) includes an entry dated April 28, 1994 relative to the NMR spectrum wherein I note the apparent success of the synthesis ("looks like product is there!"). The structure of (N,N-diethyl)-4-ureido-5,7-dichloro-2-carboxyquinoline methyl ester is:




12. On May 3, 1994, I began a synthesis wherein I first reacted triphosgene with 4-tosylamino-5,7-dichloro-2-carboxyquinoline methyl ester to attach triphosgene's carbonyl group [CO] to the 4-amino group and then reacted diethylamine to attach the secondary amine [N] to the carbonyl group [CO]. I recorded this experiment on pages 94A-81, 94A-83 and 94A-85 of my Lab Book (Nichols Exhibit 2032), which also documents the expected product having a 4-diethyl urea substitution ((N,N-diethyl)-4-ureido-5,7-dichloro-2-carboxyquinoline methyl ester) on page 94A-83. The structure of (N,N-diethyl)-4-ureido-5,7-dichloro-2-carboxyquinoline methyl ester is shown above. I labeled a sample from this experiment 94A-85-I and sent a sample to UTMB's NMR facility for NMR testing.
13. On May 13, 1994, UTMB's NMR facility performed a NMR spectrum on sample 94A-85-I. A spectrum data sheet (Nichols Exhibit 2034) was generated from the NMR spectrum of sample 94A-85-I, which includes a drawing of the chemical structure of (N,N-diethyl)-4-ureido-5,7-dichloro-2-carboxyquinoline methyl ester that was subsequently added to the data sheet by me. The NMR test results are consistent with the chemical structure of (N,N-diethyl)-4-ureido-5,7-dichloro-2-carboxyquinoline methyl ester. Page 94A-85 of my Lab Book (Nichols Exhibit 2032) includes an entry dated May 13, 1994 relative to the NMR spectrum wherein I note the apparent success of the synthesis ("proton NMR hits!!").
14. On July 1, 1994, I began a synthesis wherein I first reacted triphosgene with 4-tosylamino-5,7-dichloro-2-carboxyquinoline ethyl ester to attach triphosgene's carbonyl group [CO] to the 4-amino group and then reacted diethylamine to attach the secondary amine [N] to the carbonyl group [CO]. I recorded this experiment on pages 94B-20 and 94B-27 of my Lab Book (Nichols Exhibit 2022), which also documents the expected product having a 4-diethyl urea substitution ((N,N-diethyl)-4-ureido-5,7-dichloro-2-carboxyquinoline ethyl ester) on page 94B-20. I labeled a sample from this experiment

94B-27-I and sent 10 mg of 94B-27-I for elemental analysis. Elemental analyses are used to identify chemical structures. On July 22, 1994, I entered the results of the elemental analysis on page 94B-27 of my Lab Book (Nichols Exhibit 2022). The structure of (N,N-diethyl)-4-ureido-5,7-dichloro-2-carboxyquinoline ethyl ester is:




15. On July 22, 1994, after receiving the results of the elemental analysis for 94B-27-I, I sent 300 mg of sample 94B-27-I ((N,N-diethyl)-4-ureido-5,7-dichloro-2-carboxyquinoline ethyl ester) to NIH for anticonvulsant testing along with an Antiepileptic Drug Development (ADD) Registration Record (Nichols Exhibit 2037) showing the chemical structure of (N,N-diethyl)-4-ureido-5,7-dichloro-2-carboxyquinoline ethyl ester, its molecular weight, its molecular formula, and indicating that the compound had been identified by elemental analysis. The ADD Registration Record for sample 94B-27-I was processed by NIH on August 1, 1994, and assigned identification number ADD # 236001. Sample 94B-27-I (ADD # 236001) was tested on mice by NIH on August 20, 1994, and August 31, 1994. The August 31, 1994 test results (Nichols Exhibit 2023) indicated anticonvulsant activity of the compound. Specifically, the Threshold Tonic Extension (TTE) Test indicated protective activity at the 2-hour time interval.
16. On July 13, 1994, I began a synthesis wherein I first reacted triphosgene with 4-tosylamino-5,7-dichloro-2-carboxyquinoline ethyl ester to attach triphosgene's carbonyl group [CO] to the 4-amino group and then reacted diphenylamine to attach the secondary amine [N] to the carbonyl group [CO]. I recorded this experiment on pages 94B-25 and 94B-32 of my Lab Book (Nichols Exhibit 2024), which also documents the expected product having a 4-diphenyl urea substitution ((N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxyquinoline ethyl ester) on page 94B-25. I labeled a sample from this experiment 94B-32-III. The structure of (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxyquinoline ethyl ester is:




17. I sent a sample of 94B-32-III for mass spectral analysis. On August 10, 1994, a fast atom bombardment (FAB) mass spectrum was performed in the Analytical Chemistry Center of the University of Texas Medical School in Houston on 94B-32-III. FAB mass spectra are used to identify chemical structures. A spectrum data sheet was generated from the FAB spectrum of 94B-32-III (page 2 of Nichols Exhibit 2039), which includes a drawing of the chemical structure of (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxyquinoline ethyl ester that was subsequently added to the data sheet by me. The mass spectral test results are consistent with the chemical structure of (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxyquinoline ethyl ester. Page 94B-32 of my Lab Book (Nichols Exhibit 2024) includes an entry dated August 12, 1994 relative to the mass spectrum wherein I note the apparent success of the synthesis ("got great mass spectrum").
18. On August 12, 1994, after receiving results of the mass spectrum of sample 94B-32-III, I sent 280 mg of 94B-32-III ((N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxyquinoline ethyl ester) to NIH for anticonvulsant testing along with an Antiepileptic Drug Development (ADD) Registration Record (Nichols Exhibit 2040) showing the chemical structure of (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxyquinoline ethyl ester, its molecular weight, its molecular formula, and indicating that the compound had been identified by mass spectrum. The ADD Registration Record for sample 94B-32-III was processed by NIH on August 30, 1994, and assigned identification number ADD # 236075. Sample 94B-32-III (ADD # 236075) was tested on mice by NIH on September 30, 1994, and October 4, 1994. The October 4, 1994 test results (page 3 of Nichols Exhibit 2025) indicated anticonvulsant activity of the compound. Specifically, the TTE Test indicated protective activity at the .25-hour and 2-hour time intervals.
19. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these

statements were made with the knowledge that willful false statements and the like made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the patent at issue in this interference.


Executed on January 30, 2007.

A handwritten signature in cursive script, appearing to read "Alfred C. Nichols", is written over a horizontal line.

Alfred C. Nichols




have 4g left from page 24; placed in 500 ml round bottom & cooled in ice water bath; also cooled 50 ml of 90% H_2SO_4 in ice water bath; added the acid to suspension & let sit at $0^\circ C$ for 2 hr; poured over ice; collected ten precipitate over vacuum; ran on TLC in 011; starting material gave fluorescent spot at solvent front; 43-T gave one spot at $R_f = 0.92$




placed 2.6g of 43-T in 1 l round bottom w 3 ports; cooled in ice water bath & added 50 ml anhydrous pyridine; added condenser & dropping funnel & covered w N_2 ; under hood weighed out 1.3g triphosgene & added to pyridine soln; covered w N_2 & let stir at $0^\circ C$ for 2 hr; ~~then added~~ ~~dropwise~~ 1.2 ml diethylamine dissolved in 20 ml anhydrous pyridine; flushed w N_2 gas then added dropwise 1.2 ml diethylamine dissolved in 20 ml anhydrous pyridine 30 min then at RT for 3 hr

Nichols EXHIBIT 2020

BEST AVAILABLE COPY



have 4g left from page 24; placed in 500 ml round bottom & cooled in ice water bath; also cooled 50 ml of 90% H₂SO₄ in ice water bath; added the acid to indole & stirred at 0°C for 2 hr; poured over ice; collected ten precipitates over vacuum; ran on TLC in D14: starting material gave fluorescent spot at solvent front; 43-T gave one spot at R_f = 0.92




placed 2.6g of 43-T in 1 l round bottom w 3 parts; cooled in ice water bath & added 50 ml anhydrous pyridine; added condenser & dropping funnel & covered w N₂; under hood weighed out 1.3g triphosgene & added to pyridine soln; covered w N₂ & let stir at 0°C for 2 hr; then added dropwise 1.2 ml diethylamine dissolved in 20 ml anhydrous pyridine; stirred at 0°C for 30 min then at R_t for 30 min; poured over ice

all pool 59


063

ce 4/11



cooled in ice water bath


in dry 250 round bottom w 2 ports
 placed 1g of 50-II & 10 ml of anhydrous
 pyridine; added condenser & tried to
 add 2.2 g triphosgene propylene
 but this did not work well →
 it started reacting when pyridine
 was added then did not dissolve
 well in anhydrous THF; let
 warm up to room temp & stirring
 & continue to stir at rt for 5 hrs



bubbled N₂ gas through reaction mixture
 then added 2.8 ml of diethylamine - this
 is more than enough to tie up unreacted
 phosgene; let stir at rt for 1 1/2 hrs &
 poured over ice; shook out 3X w CHCl₃,
 combined & filtered over magnesium sulfate
 4/12 ran on TLC in OH; 50-II give
 fluorescent spot at solvent front; 63-II
 give spot at solvent front that does
 not fluoresce
 evaporated of CHCl₃ under
 vac.


Nichols EXHIBIT 2030

BEST AVAILABLE COPY



cooled in ice water bath

in dry 250 round bottom in 2 parts placed 1g of 50-II & 10 ml of anhydrous pyridine; added condenser & tried to add 2.2 g triphosgene. Triphosgene but this did not work well \rightarrow it started reacting when pyridine was added. They did not dissolve well in anhydrous THF. Let warm up to room temp in stirring & continue to stir at r.t. for 5 hrs




bubbled N_2 gas through reaction mixture then added 2.8 ml of dichloromethane - this is more than enough to tie up unreacted phosgene; let stir at r.t. for 1 1/2 hrs & poured over ice; shook out 3X w/ CHCl_3 , combined & filtered over magnesium sulfate. 4/12 ran on TLC in OH; 50-II give fluorescent spot at solvent front; 63-II give spot at solvent front that does not give fluorescence evaporated of CHCl_3 under hood

from page 63

4/12

UB4



63-II

recovered dark oil from 63-II that smelled like pyridine; added ethylare chloride & shook out 2x w/ H_2O ; filtered over magnesium sulfate & evaporated under hood to dark oil; added a little hexane — nothing dissolved; decanted hexane & added ethyl ether; most of the residue dissolved; filtered & added a little MeOH to filtrate; labeled as 64-II; placed under hood & hoped like hell something would crystallize — it didn't; next dissolved in MeOH & filtered again; ran on TLC in O/H \rightarrow spot at solvent front which is slightly fluorescent


4/28 - NMR: not pure — see too many aromatic carbons — but looks like product is there!

Low — $CH_2 - CH_3$, 3 C-H aromatic carbons, methoxy methyl


5/5 stirred in dilute NaOH — yellow color went into aqueous; filtered & made filtrate

III as acid; got formation of yellow precipitate; labeled as 64-III


5/6 ran 64-III on TLC in O/H; got large spot at R_F 0.45 which matched 85-I; also got two smaller spots below this



TOS 5/3




TOS-NCO



5g

in dry 1l round bottom placed 5g of dry 93B-97-II, 200 ml anhydrous acetonitrile & 7g p-toluenesulfonic anhydride; covered w N₂ added lit coal; collected yellow precipitate over vacuum; ran on TLC in D.I.: 81-I gone 97-II gone fluorescent spot at R_f = 0.88 that did not fluoresce




triphsosgene

mw = 297

use


2.5g = 3X

2.0



3.5g
mw = 425
(0.0082 moles)

in dry 250 ml round bottom w 2 ports placed 3.5g of 81-I & cooled in ice water bath; added 2g (0.0067 moles → 0.02 moles phosgene or 2.5X), triphosgene & 10 ml THF (anhydrous); w stirring added 10 ml anhydrous pyridine; color of suspension changed from yellow to white then back to yellow; let warm to room temp & stir for 1 1/2 hr




use

0.09 moles (mw = 73 → 2.9g → 4.1 ml)


added 4.1 ml of diethyl ether to 81-I & let stir

mixture turned dark brown

Nichols EXHIBIT 2032




TOS-NCC



93B-97-II

5g

in dry 1L round bottom placed 5g of dry 93B-97-II, 200 ml anhydrous acetonitrile & 7g p-toluenesulfonyl isocyanate; covered w N₂ added condenser & heated to reflux for 3 hr; let cool; collected yellow precipitate over vacuum; ran on TLC in 0:1:1 81-I gave spot at R_f = 0.88 that did not fluoresce; 97-II gave fluorescent spot at R_f = 0.15



3.5g

MW=425

(0.0082 moles)


triphsosgene

MW=297

use


2.5g = 3X

2.0



new 6.5g drug mixture

in dry 250 ml round bottom in 2 parts placed 3.5g of 81-I & cooled in ice water bath; added 2g (0.0067 moles → 0.02 moles phosgene or 2.5X), triphosgene & 10 ml THF (anhydrous); w stirring added 10 ml anhydrous pyridine; suspension changed from yellow to white then back to yellow; let warm to room temp & stir for 1 1/2 hr



+ HN


use Et

0.04 moles (MW=73 → 2.9g → 4.1 ml) Et₃N

added 4.1 ml of diethyl amine, dropwise to 81-I & let stir at r.t. for 1 hr; mixture turned dark brown; poured over ice to

from page 81


5/4



81-III

4X w CHCl_3 ,
 combined organic fractions &
 filtered over magnesium sulfate;
 run on TLC in O/H : 81-III gave
 2 spots — fluorescent spot at solvent
 front & non-fluorescent spot at $R_f = 0.95$
 which matched 81-I — This looks good!

evaporated off CHCl_3 & recovered
 dark oil that smelled like pyridine;
 cooled in ice water bath.




cooled 20 ml of 90% H_2SO_4 in ice
 water bath; w stirring slowly added
 the acid to 81-III; let stir at 0°C
 for 1 1/4 hr; poured over ice; slowly
 raised pH w NaOH ; at pH 0.75 got
 formation of small amt of orange goo;
 filtered out goo & labeled as 83-II — goo
 soluble in acetone; continued to
 raise pH of filtrate.

5/5 raised pH to 6.3 — shook out
 4X w ethyl acetate; dried 83-II
 in ethyl acetate (it had formed orange crystals
 as acetone evaporated); combined acetate
 fractions & filtered over a little FeSO_4 ;
 labeled as 83-III; run on TLC in O/H ;
 got large fluorescent spot at solvent front
 & small spot at $R_f = 0.40$; (4-N H_2
 also gives fluorescent spot at solvent front —
 see 93 B-100); run TLC in ethylene chloride;
 small spot at origin & fluorescent spot at

from page 83

5/5

085

1)  reduced mol
 of 83-III + added
 a little NaOH → got
 formation of a red precipitate,
 collected over vacuum, washed
 in a little CHCl₃ & let air dry,
 labeled as 85-I

5/6

ran TLC on 85-I in OH → one spot
 at R_F = 0.45 that did not fluoresce

	expected	found	expected by sulfate salt
C = 16 = 192 =	51.39%	42.15	41.0%
H = 17 = 17 =	4.59	3.96	4.1
N = 3 = 42 =	11.35	8.45	9.0
O = 3 = 48 =	12.97		
Cl = 2 = 71 =	19.19		
	370	99.99	

5/13 proton NMR hits!!

ran mp = 260°C dec; ran 10 mg in
 analysis; somewhat soluble in CHCl₃

elemental analysis off but ratios are
 close

	expected	found
H/C	0.09	0.09
N/C	0.22	0.20
H/N	0.40	0.47

Need to
 purify &
 get NMR or
 mass spec


5/12 stirred 83-III in 6N HCl & filtered
 over a little Iron wool; raised pH
 of filtrate w/ NaOH.

5/13 proton NMR hit — soluble in H₂O
 & not soluble in acetone — probably
 sulfate salt (MW = 468)

5/18 got good carbon NMR

8/2/9

BEST AVAILABLE COPY






3-MAY-94 11:25:24

PEAK 7
 MXINT 723012600
 RESOL 0.3663575 Hz
 RESOL 0.0013560 ppm
 EXREF 2.0400000 ppm
 OBS -1767.08 Hz
 ABOBS 270168.1000000 KHz
 NGAIN 11
 COMNT DM3:E134AN01;94A-85-I;D2O+D6-ACETN:1H




NO.	PPM	INT(%)	FREQ(Hz)	POSITION	BAR GRAPH
1	7.9917	7.50493	2159.08	7122	++
2	7.8629	7.05058	2124.28	7217	+
3	7.4140	6.11066	2003.01	7548	+
4	4.6531	100.00000	1257.11	9584	+++++
5	3.3282	15.67389	899.18	10561	+++
6	1.8013	35.10741	486.66	11687	+++++
7	1.1274	33.39196	304.58	12184	+++++

Nichols EXHIBIT 2034




BEST AVAILABLE COPY



in dry 250 ml round bottom in 2 parts
 placed 5g of dry 94A-99-II & cooled
 in ice water bath; added 2.9g tripropylamine
 (excess); ~~added~~ covered in N₂ & added
 condenser & dropping funnel; dropwise
 in stirring added 50 ml acetic anhydride
 pyridine (do not have any THF);
 let warm to r.t. & stir for 1 hr;






flushed 20-T in N₂; added 5 ml
 diethylamine dropwise; yellow color
 turned dark brown; let stir at r.t.
 for 2 hr; poured over ice; collected
 rough precipitate over vacuum; washed
 in H₂O & let air dry; ran on TLC in O.H.
 20-T gave one spot at solvent front;
 99-II gave one spot at R_F = 0.91




cooled 20-T in ice water bath; added cooled
 20 ml 90% H₂SO₄; added acid slowly to compound
 & let stir at 0°C for 2 hr; poured over ice;
 added a little NaOH; collected yellow precipitate
 over vacuum; ran on TLC in O.H. - one spot
 at solvent front; both II

Nichols EXHIBIT 2022


Important: Place card under




in dry 250 ml round bottom in 2 parts
 placed 5g of dry 94A-99-III & cooled
 in ice water bath; added 2.9g triethylamine
 (excess); ~~added~~ covered in N₂ & added
 condenser & dropping funnel; dropwise
 in stirring added 50 ml acetic anhydride
 pyridine (do not have any THF);
 let warm to r.t. & stir for 1 hr;




diethylamine



flushed 20-IT in N₂; added 5 ml
 diethylamine dropwise; yellow solid
 turned dark brown; let stir at r.t.
 for 2 hr; poured over ice; collected
 orange precipitate over vacuum; washed
 in H₂O & let air dry; ran on TLC in O.H.
 20-IT gave one spot at solvent front;
 99-III gave one spot at R_F = 0.91



90% H₂SO₄
 0°C




cooled 20-IT in ice water bath; added
 20 ml 90% H₂SO₄; added acid slowly to compound
 & let stir at 0°C for 2 hr; poured over ice;
 added a little NaOH; collected yellow precipitate
 over vacuum; ran on TLC in O.H. - one spot
 at solvent front; both II & IV are soluble in CH₂Cl₂

Important: Place card under blue conv

Name: han roel CS
 Experimr:

7/15/94

027



dried 23-III
 need to see if
 it is salt
 corrected

	found	calcd	%
C = 17	20.4	55.43	53.13
H = 19	19	5.16	4.95
N = 3	4.2	11.41	10.94
O = 3	3.2	8.70	12.50
Cl = 2	71	19.29	18.49
	368	99.99%	

computer for
 $N_3 C_{17} H_{20}$

ran MP = 90°C
 sent 10 mg for analysis

for $K_2 H_2 SO_4$
 expected
 C = 48.92
 H = 4.80
 N = 10.07

9/26 octon
 in TTE
 test at
 100 mg/kg

in 1 $H_2 O$
 C = +2.15%
 H = +10.28%
 N = +3.8%

in $\frac{1}{2} H_2 SO_4$
 C = -5.45%
 H = -2.24%
 N = -3.91%

2/12 in 1 $H_2 O$
 C = 50.75
 H = 5.22
 N = 10.45
 O = 15.92
 Cl = 17.66
 100.00

in $\frac{1}{2} H_2 SO_4$
 C = 47.11
 H = 4.62
 N = 9.70

this looks
 like + 1 $H_2 O$

$C_{17} H_{21} N_3 O_4 Cl_2$
 MW = 402

sent 300 mg to NIH
 sent 100 mg to Larry Snel

NIH # 238001

NATIONAL INSTITUTES OF HEALTH

ADD REGISTRATION RECORD

Complete one (1) form (both sides) for each compound.
Duplicate information need not be repeated.

8/1/94

v-p 419

ADD #

00236008

NAME OF SUPPLYING ORGANIZATION

University of Texas Medical Branch

DIRECT CORRESPONDENCE TO:

LAST NAME

Nichols

FIRST NAME

Al

INITIAL

C

DEGREE

Ph.D.

STREET ADDRESS

Pharmacology J-31

CITY

Galveston

STATE

TX

ZIP CODE

77555

TELEPHONE (Area Code)


0917721 9659

COMPOUND IDENTIFICATION

94B-27-1

CHEMICAL NAME (If Known)

STRUCTURE



MOLECULAR WEIGHT

402

MOLECULAR FORMULA

C 17 H 21 N 03 O 04

CA ☐ ☐ P ☐ ☐ CL 02 S ☐ ☐NA ☐ ☐ F ☐ ☐ MG ☐ ☐ K ☐ ☐

MELTING POINT

(°C) 90

BOILING POINT

(°C)

DECOMPOSITION

☐ YES ☒ NO

DATE PURITY WAS LAST ASCERTAINED

7/20/94

BY WHAT METHOD

☒ CNH ANALYSIS
☐ OTHER (Specify)

DATE COMPOUND SHIPPED TO NINDS

7/22/94

NUMBER OF CONTAINERS SHIPPED

WEIGHT OF COMPOUND SHIPPED (mg.)

300

IF COMPOUND IS A DUPLICATE OF PREVIOUSLY TESTED COMPOUND

☒ PLEASE RETURN TO SUPPLIER☐ IT IS NOT NECESSARY TO RETURN COMPOUND TO SUPPLIER.
COMPOUND MAY BE USED AT NINDS DISCRETION FOR ANTI-
CONVULSANT TESTING IN ANIMALS ONLY.

236001

A. STATE OF DEVELOPMENT		B. STATE OF DEVELOPMENT (Continued)																																																				
PATENTED <input type="checkbox"/> YES (If yes, indicate proposed use in B block) <input type="checkbox"/> NO NUMBER _____ YEAR _____ IND <input type="checkbox"/> YES (If yes, indicate proposed use in B block.) <input type="checkbox"/> NO DATE FILED: _____ KNOWN ACTIONS IN MAN — IF ANY (Indicate in B block.) MARKETED <input type="checkbox"/> YES (If yes, indicate approved use in B block.) <input type="checkbox"/> NO YEAR NDA APPROVAL <div style="border: 1px solid black; width: 100px; height: 40px; margin: 10px 0;"></div>		<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th>KNOWN ACTIONS</th> <th>IND</th> <th>NDA</th> <th>PROPOSED OR APPROVED USE IN MAN</th> </tr> </thead> <tbody> <tr><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td>ANTIEPILEPTIC</td></tr> <tr><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td>NEUROLOGIC OTHER THAN ANTI-EPILEPTIC SEDATIVE — HYPNOTIC</td></tr> <tr><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td>TRANQUILIZER</td></tr> <tr><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td>MUSCLE RELAXANT</td></tr> <tr><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td>STIMULANT, MOOD ELEVATOR</td></tr> <tr><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td>ANALGESIC</td></tr> <tr><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td>ANTICHOLINERGIC</td></tr> <tr><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td>OTHER _____</td></tr> <tr><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td>OTHER SYSTEM (Non CNS) (Specify in COMMENTS)</td></tr> </tbody> </table>					KNOWN ACTIONS	IND	NDA	PROPOSED OR APPROVED USE IN MAN	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	ANTIEPILEPTIC	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	NEUROLOGIC OTHER THAN ANTI-EPILEPTIC SEDATIVE — HYPNOTIC	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	TRANQUILIZER	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	MUSCLE RELAXANT	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	STIMULANT, MOOD ELEVATOR	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	ANALGESIC	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	ANTICHOLINERGIC	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	OTHER _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	OTHER SYSTEM (Non CNS) (Specify in COMMENTS)								
KNOWN ACTIONS	IND	NDA	PROPOSED OR APPROVED USE IN MAN																																																			
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	ANTIEPILEPTIC																																																			
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	NEUROLOGIC OTHER THAN ANTI-EPILEPTIC SEDATIVE — HYPNOTIC																																																			
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	TRANQUILIZER																																																			
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	MUSCLE RELAXANT																																																			
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	STIMULANT, MOOD ELEVATOR																																																			
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	ANALGESIC																																																			
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	ANTICHOLINERGIC																																																			
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	OTHER _____																																																			
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	OTHER SYSTEM (Non CNS) (Specify in COMMENTS)																																																			
SPECIAL HANDLING INSTRUCTIONS (Check all appropriate boxes.) <input type="checkbox"/> UNSTABLE; COMPOUND CAN BE EXPECTED TO REMAIN STABLE FOR _____ <input type="checkbox"/> KEEP AWAY FROM HEAT <input type="checkbox"/> KEEP AWAY FROM COLD <input type="checkbox"/> DO NOT EXPOSE TO LIGHT <input type="checkbox"/> INVESTIGATIVE DRUG, NOT FOR HUMAN USE <input type="checkbox"/> OTHER _____		WE CAN SUPPLY ADDITIONAL SAMPLES OF COMPOUND (Check appropriate box.) <table style="width:100%;"> <tr> <td></td> <td style="text-align: center;">500-1,000 mg</td> <td style="text-align: center;">~1,000 mg</td> </tr> <tr> <td>IMMEDIATELY UPON REQUEST</td> <td style="text-align: center;"> </td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>WITHIN 4 WEEKS</td> <td style="text-align: center;"> </td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>WITHIN 12 WEEKS</td> <td style="text-align: center;">X</td> <td style="text-align: center;">X</td> </tr> <tr> <td>NOT AT ALL</td> <td style="text-align: center;"> </td> <td style="text-align: center;"> </td> </tr> </table>						500-1,000 mg	~1,000 mg	IMMEDIATELY UPON REQUEST		<input type="checkbox"/>	WITHIN 4 WEEKS		<input type="checkbox"/>	WITHIN 12 WEEKS	X	X	NOT AT ALL																																			
	500-1,000 mg	~1,000 mg																																																				
IMMEDIATELY UPON REQUEST		<input type="checkbox"/>																																																				
WITHIN 4 WEEKS		<input type="checkbox"/>																																																				
WITHIN 12 WEEKS	X	X																																																				
NOT AT ALL																																																						
KNOWN DATA — ANIMALS <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th></th> <th>ROUTE</th> <th>SPECIES</th> <th>TIME OF EFFECT</th> <th>REFERENCE</th> </tr> </thead> <tbody> <tr><td>LD₅₀ mg/kg</td><td></td><td></td><td></td><td></td></tr> <tr><td>LD₅₀ mg/kg</td><td></td><td></td><td></td><td></td></tr> <tr><td>MAXIMAL ELECTROSHOCK ED₅₀ mg/kg</td><td></td><td></td><td></td><td></td></tr> <tr><td>OTHER ANTICONVULSANT TEST ED₅₀</td><td></td><td></td><td></td><td></td></tr> <tr><td>TOXICITY — KIND, DOSE</td><td></td><td></td><td></td><td></td></tr> <tr><td>TOXICITY — KIND, DOSE</td><td></td><td></td><td></td><td></td></tr> <tr><td>OTHER — SPECIFY EFFECT, DOSE</td><td></td><td></td><td></td><td></td></tr> <tr><td>OTHER — SPECIFY EFFECT, DOSE</td><td></td><td></td><td></td><td></td></tr> <tr><td>OTHER — SPECIFY EFFECT, DOSE</td><td></td><td></td><td></td><td></td></tr> </tbody> </table>			ROUTE	SPECIES	TIME OF EFFECT	REFERENCE	LD ₅₀ mg/kg					LD ₅₀ mg/kg					MAXIMAL ELECTROSHOCK ED ₅₀ mg/kg					OTHER ANTICONVULSANT TEST ED ₅₀					TOXICITY — KIND, DOSE					TOXICITY — KIND, DOSE					OTHER — SPECIFY EFFECT, DOSE					OTHER — SPECIFY EFFECT, DOSE					OTHER — SPECIFY EFFECT, DOSE					COMMENTS <div style="border: 1px solid black; height: 40px; margin-top: 5px;"></div>		
	ROUTE	SPECIES	TIME OF EFFECT	REFERENCE																																																		
LD ₅₀ mg/kg																																																						
LD ₅₀ mg/kg																																																						
MAXIMAL ELECTROSHOCK ED ₅₀ mg/kg																																																						
OTHER ANTICONVULSANT TEST ED ₅₀																																																						
TOXICITY — KIND, DOSE																																																						
TOXICITY — KIND, DOSE																																																						
OTHER — SPECIFY EFFECT, DOSE																																																						
OTHER — SPECIFY EFFECT, DOSE																																																						
OTHER — SPECIFY EFFECT, DOSE																																																						

Could you please supply more submission forms

BEST AVAILABLE COPY

14

ANTICONVULSANT SCREENING PROJECT TEST RESULTS


THRESHOLD TONIC EXTENSION (TTE) TEST: Mice, i.p.

ADD # 236001 Supplier Code: 419 Date: 31-Aug-94
 Solvent: MC (M&P, SB)
 Reference: 266:2 Animal Weight: 21.0 to 25.0 g

Dose (mg/kg)	# Protected/# Tested						
	.25 hr	.5 hr	1 hr	2 hr	4 hr	6 hr	8 hr
<u>100</u>	<u>0 / 4</u>	<u>0 / 4</u>	<u>0 / 4</u>	<u>1 / 4</u>	<u>0 / 4</u>	<u> / </u>	<u> / </u>
<u> </u>	<u> / </u>	<u> / </u>	<u> / </u>	<u> / </u>	<u> / </u>	<u> / </u>	<u> / </u>

MES Confirmation


Dose (mg/kg)	# Protected/# Tested						
	.25 hr	.5 hr	1 hr	2 hr	4 hr	6 hr	8 hr
<u> </u>	<u> / </u>	<u> / </u>	<u> / </u>	<u> / </u>	<u> / </u>	<u> / </u>	<u> / </u>




94B-27-±

7/13/94


025



in dry 250 ml round bottom in 2 parts
~~1st~~ added 5g of 94A-99-III, cooled
 in ice water bath; added 2.9g triphosgene,
 covered in N₂ & added condenser & dropping
 funnel; added dropwise 50 ml anhydrous
 pyridine in stirring; had evolution of
 gas, let warm to r.t. & stir for 1 hr;
 flushed in N₂ gas



dropwise added 8.2g of diphenylamine
 dissolved in 40 ml of pyridine to 25-I;
 got great crimson color; let stir
 at r.t. for 2 hrs; poured over a
 lot of ice; collected orange precipitate
 over vacuum




stirred 25-II in ice water bath; added 30 ml
 of 90% H₂SO₄; let stir at 0°C for 2 hrs;
 poured over ice; collected gummy precipitate
 over vacuum


7/14 ran an TLC in ethylene chloride; diphenyl
 amine gives one spot at R_F 0.94; III
 gives small spot here &
 chloride part of III gives
 spot at 0.94

Nichols EXHIBIT 2024


BEST AVAILABLE COPY



in dry 250 ml round bottom in 2 parts
~~then~~ placed 5g of 94A-99-III, cooled
 in ice water bath; added 2.9g triphosgene,
 covered in N_2 & added condenser & dropping
 funnel; added dropwise 50 ml anhydrous
 pyridine w/ stirring; had evaluation of
 prod; let warm to r.t. & stir for 1 hr;
 flushed in N_2 gas




dropwise added 8.2g of diphenylamine
 dissolved in 40 ml of pyridine to 25-I;
 got great crimson color; let stir
 at r.t. for 2 hrs; poured over a
 lot of ice; collected orange precipitate
 over vacuum



stirred 25-II in ice water bath; added 30 ml
 of 90% H_2SO_4 ; let stir at $0^\circ C$ for 2 hrs;
 poured over ice; collected gummy precipitate
 over vacuum

7/14 ran on TLC in ethylene chloride; diphenyl
 amine gives one spot at Rf 0.94; III residue
 gives small spot here & spot at origin; ethylene
 chloride wash of III gives large spot at origin & large
 spot at 0.94



observed 26-II in
ethyl acetate is a little
reacting; reduced val by
about $\frac{1}{3}$ & added & equal
val of hexane; let sit
overnight

7/26 added a little more hexane & collected
white precipitate over vacuum; ran on TLC
in ethyl ether; precipitate gave
one distinct spot at $R_F = 0.31$; the
filtrate gave a streak to 0.31

ran mp = 195°C sharp

7/29 took some remaining 26-II &
H stirred in 6N HCl & filtered; labeled
it as undissolved residue as 32-II; added
up 2 NaOH to the filtrate & labeled
it as 32-III

8/1 made 32-III basic in NaOH but
nothing fell out;

ran TLC on 32-I & 32-II \rightarrow each
gives one spot at $R_F = 0.23$ in ethyl
ether

8/4 have NMR that seems to fit;
product decomposes when heated to 80°C
in DMSO — on NMR looks like hydrolysis
giving off diphenyl amine & forming 'N-COOH'

C = 25 = 300

H = 19 = 19

N = 3 = 42

O = 3 = 48

Cl = 2 = 71

480

Calcd mass spectrum:

479 & 481


got great mass spectrum;

sent 290 mg to NIH

10 mg to Larry Snell

NIH # 236075

Important: Place card under blue cover



Medical School
Analytical Chemistry Center

FAX TRANSMITTAL SHEET

DATE: August 11, 1994

TO: Dr. Al Nichols
Department of Pharmacology
UTMB-Galveston

FAX NUMBER: (409) 772-9642

FROM: William E. Seifert, Jr., Ph.D. *Bill*
Assistant Director
Analytical Chemistry Center
The University of Texas Medical School at Houston
6431 Fannin, Rm. 6.130 MSB
Houston, TX 77030

Telephone: (713) 792-5612
FAX: (713) 794-4226

Following is the FAB mass spectrum obtained from the analysis of your sample 94B-32-III. As you can see from the spectrum, the expected $[M+H]^+$ at m/z 480.1 was observed and with the expected isotope ratio for a compound containing two Cl atoms.


If you have any questions regarding these analyses, please do not hesitate to contact me.

TOTAL PAGES INCLUDING THIS SHEET: 5

UT-Houston M. Nichols EXHIBIT 2039

6431 Fannin Street • P.O. Box 20706 • Houston, Tex

Located in the Texas



Medical School
Analytical Chemistry Center

FAX TRANSMITTAL SHEET

DATE: August 11, 1994

TO: Dr. Al Nichols
Department of Pharmacology
UTMB-Galveston

FAX NUMBER: (409) 772-9642

FROM: William E. Seifert, Jr., Ph.D. *Bill*
Assistant Director
Analytical Chemistry Center
The University of Texas Medical School at Houston
6431 Fannin, Rm. 6.130 MSB
Houston, TX 77030

Telephone: (713) 792-5612
FAX: (713) 794-4226

Following is the FAB mass spectrum obtained from the analysis of your sample 94B-32-III. As you can see from the spectrum, the expected $[M+H]^+$ at m/z 480.1 was observed and with the expected isotope ratio for a compound containing two Cl atoms.


If you have any questions regarding these analyses, please do not hesitate to contact me.

TOTAL PAGES INCLUDING THIS SHEET: 5


UT-Houston Medical School

6431 Fannin Street • P.O. Box 20708 • Houston, Texas 77225 • (713) 792-5612 FAX (713) 794-4226

Located in the Texas Medical Center



nichols, 94b-32-III 10 Aug 94 11:38 am HRP +FAB
08100005 scans 3-10 100%= 35204mV



NATIONAL INSTITUTES OF HEALTH

ADD REGISTRATION RECORD

Complete one (1) form (both sides) for each compound.
Duplicate information need not be repeated.

NAME OF SUPPLYING ORGANIZATION

University of Texas Medical Branch

DIRECT CORRESPONDENCE TO:

LASTNAME

Nichols

FIRST NAME

H1

INITIAL

C

DEGREE

Ph.D.

STREET ADDRESS

Pharmacology J-31

CITY

Galveston

STATE

TX

ZIP CODE

77555

TELEPHONE (Area Code)


409 772 9659

COMPOUND IDENTIFICATION

94 B-32 -H1

CHEMICAL NAME (If Known)

STRUCTURE



MOLECULAR WEIGHT

480

MOLECULAR FORMULA

C 25 H 19 N 03 O 03

CA

P

CL 02

S

NA

F

MG

K

MELTING POINT

(°C) 195

BOILING POINT

(°C)

DECOMPOSITION

☐ YES ☒ NO

DATE PURITY WAS LAST ASCERTAINED

8 11 94

BY WHAT METHOD

☐ CNH ANALYSIS☒ OTHER (Specify) mass spectrum

DATE COMPOUND SHIPPED TO NINDS

8 12 94

NUMBER OF CONTAINERS SHIPPED

WEIGHT OF COMPOUND SHIPPED (mg.)

280

IF COMPOUND IS A DUPLICATE OF PREVIOUSLY TESTED COMPOUND

☒ PLEASE RETURN TO SUPPLIER☐ IT IS NOT NECESSARY TO RETURN COMPOUND TO SUPPLIER.
COMPOUND MAY BE USED AT NINDS DISCRETION FOR ANTI-
TESTING IN ANIMALS ONLY.

236075

A. STATE OF DEVELOPMENT

PATENTED ☐ YES (If yes, indicate proposed use in B block) ☐ NO

NUMBER YEAR

IND ☐ YES (If yes, indicate proposed use in B block) ☐ NO

DATE FILED:

KNOWN ACTIONS IN MAN — IF ANY (Indicate in B block.)

MARKETED ☐ YES (If yes, indicate approved use in B block) ☐ NO

YEAR NDA APPROVAL

B. STATE OF DEVELOPMENT (Continued)

KNOWN ACTIONS IND NDA PROPOSED OR APPROVED USE IN MAN

- ☐ ☐ ☐ ANTI-EPILEPTIC
NEUROLOGIC OTHER THAN ANTI-EPILEPTIC SEDATIVE — HYPNOTIC
- ☐ ☐ ☐ TRANQUILIZER
- ☐ ☐ ☐ MUSCLE RELAXANT
- ☐ ☐ ☐ STIMULANT, MOOD ELEVATOR
- ☐ ☐ ☐ ANALGESIC
- ☐ ☐ ☐ ANTICHOLINERGIC
- ☐ ☐ ☐ OTHER _____
- ☐ ☐ ☐ OTHER SYSTEM (Non CNS)
(Specify in COMMENTS)

SPECIAL HANDLING INSTRUCTIONS
(Check all appropriate boxes.)☐ UNSTABLE; COMPOUND CAN BE EXPECTED TO REMAIN STABLE FOR _____

- ☒ KEEP AWAY FROM HEAT *decomposes when heated*
- ☐ KEEP AWAY FROM COLD *when heated*
- ☐ DO NOT EXPOSE TO LIGHT *in aqueous solution*
- ☐ INVESTIGATIVE DRUG, NOT FOR HUMAN USE
- ☐ OTHER

WE CAN SUPPLY ADDITIONAL SAMPLES OF COMPOUND
(Check appropriate box.)

- | | 500-1,000 mg | >1,000 mg |
|--------------------------|-------------------------------------|-------------------------------------|
| IMMEDIATELY UPON REQUEST | <input type="checkbox"/> | <input type="checkbox"/> |
| WITHIN 4 WEEKS | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |
| WITHIN 12 WEEKS | <input type="checkbox"/> | <input type="checkbox"/> |
| NOT AT ALL | <input type="checkbox"/> | <input type="checkbox"/> |

KNOWN DATA — ANIMALS	ROUTE	SPECIES	TIME OF EFFECT	REFERENCE
LD ₅₀ mg/kg				
LD ₅₀ mg/kg				
MAXIMAL ELECTROSHOCK ED ₅₀ mg/kg				
OTHER ANTICONVULSANT TEST ED ₅₀				
TOXICITY — KIND, DOSE				
TOXICITY — KIND, DOSE				
OTHER — SPECIFY EFFECT, DOSE				
OTHER — SPECIFY EFFECT, DOSE				
OTHER — SPECIFY EFFECT, DOSE				
COMMENTS				

BEST AVAILABLE COPY

16



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
National Institutes of Health

National Institute of Neurological
Disorders and Stroke
Preclinical Pharmacology Section
Epilepsy Branch
7550 Wisconsin Avenue, MSC 9020
Federal Building, Room 114
Bethesda, Maryland 20892-9020
Phone Number: (301) 496-1846
FAX Number: (301) 496-9916

October 13, 1994

Dr. Al C. Nichols
Medical Branch
University of Texas
Pharmacology Building, J-31
Galveston, TX 77550

Dear Dr. Nichols:

Testing was recently completed for your compound ADD 236075. It was screened in both our standard identification screens as well as the new TTE test. The compound was not active in the standard screens but showed some protection at 1/4 and 2 hours in the TTE test. At this time this level of activity is not quite enough to qualify for additional tests. As more information is obtained from other TTE experiments we may change the criteria. If this occurs I will contact you possibly further considering some of your compounds.

In the meantime if you have any questions please feel free to contact me.

Sincerely yours,

James P. Stables
Assistant Chief
Preclinical Pharmacology Section
Epilepsy Branch
Division of Convulsive, Developmental
and Neuromuscular Disorders

*ADD test data on
the ethyl ester compound*

Nichols EXHIBIT 2025

BEST AVAILABLE COPY

			Time in Hours									
DOSE			0.50	4.00	0.25	1.00	2.00	3.00	6.00	8.00	#	
TEST	mg/kg	FORM	#/F CM	#/F CM	#/F CM	#/F CM	#/F CM	#/F CM	#/F CM	#/F CM	Dths	
MES	30.00	SUS	0/1	0/1								
MES	100.0	SUS	0/3	0/3								
MES	300.0	SUS	0/1	0/1								
ScMET	30.00	SUS	0/1	0/1								
ScMET	100.0	SUS	0/1	0/1								
ScMET	300.0	SUS	0/1	0/1								
TOX	30.00	SUS	0/4	0/2								
TOX	100.0	SUS	0/8	0/4								
TOX	300.0	SUS	0/4	0/2								

94B-32-III

ANTICONSULSANT SCREENING PROJECT TEST RESULTS

THRESHOLD TONIC EXTENSION (TTE) TEST: Mice, i.p.

ADD # 236075 Supplier Code: 419 Date: 4-OCT-94

Solvent: MC (M&P, SB)

Reference: 266:72 Animal Weight: 21.0 to 25.5 g

Dose (mg/kg)	# Protected/# Tested						
	.25 hr	.5 hr	1 hr	2 hr	4 hr	6 hr	8 hr
<u>100</u>	<u>1 / 4</u>	<u>0 / 4</u>	<u>0 / 4</u>	<u>2 / 4</u>	<u>0 / 4</u>	<u> </u> / <u> </u>	<u> </u> / <u> </u>
<u> </u>	<u> </u> / <u> </u>	<u> </u> / <u> </u>	<u> </u> / <u> </u>	<u> </u> / <u> </u>	<u> </u> / <u> </u>	<u> </u> / <u> </u>	<u> </u> / <u> </u>

MES Confirmation

Dose (mg/kg)	# Protected/# Tested						
	.25 hr	.5 hr	1 hr	2 hr	4 hr	6 hr	8 hr
<u>100</u>	<u>0 / 4</u>	<u> </u> / <u> </u>	<u> </u> / <u> </u>	<u>0 / 4</u>	<u> </u> / <u> </u>	<u> </u> / <u> </u>	<u> </u> / <u> </u>

